New Biomarker Panel Improves Prostate Disease Risk Stratification

Prostate disease, including benign prostatic hyperplasia (BPH) and prostate cancer (PCa), represents a significant health burden globally, with PCa being the second most common cancer in men. Current diagnostic tools, such as prostate-specific antigen (PSA) testing, often suffer from limited specificity, leading to unnecessary biopsies and overdiagnosis of indolent cancers. There is a critical need for more accurate and non-invasive methods to differentiate aggressive PCa from less harmful conditions and to improve patient risk stratification. This study addresses the urgent need for novel diagnostic biomarkers to enhance the precision of prostate disease detection and risk assessment.

The study revealed significant and distinct expression patterns for each biomarker across the different patient groups. Humanin levels were notably 2.8-fold lower in PCa patients compared to healthy controls (p<0.001), suggesting its potential as a protective factor or indicator of disease. Conversely, miR-21 expression was 3.5-fold higher in PCa patients (p<0.001), consistent with its known oncogenic role. GAS5 showed a significant 1.9-fold decrease in PCa patients (p<0.005), highlighting its tumor-suppressive properties. A combined diagnostic panel incorporating Humanin, GAS5, miR-21, and miR-103 demonstrated superior diagnostic performance, achieving an impressive Area Under the Curve (AUC) of 0.92 (with a 95% confidence interval of 0.89-0.95) for distinguishing PCa from non-cancerous conditions. This multi-marker panel exhibited a remarkable 88% sensitivity and 85% specificity in identifying prostate cancer, significantly outperforming traditional PSA testing, which showed 65% sensitivity and 70% specificity in this specific cohort. Furthermore, miR-103 levels were particularly elevated in advanced PCa cases, showing a 2.2-fold increase compared to localized disease (p<0.01), indicating its potential for staging.